BPC-157 + TB-500 Blend 10mgBPC-157 + TB-500 Blend 10mg
A two-component blend without controlled human evidence that the combination improves recovery or offers added benefit.
Answer a short online consultation. A clinician reviews it, and you only pay if treatment is approved. Dispensed by our licensed facility.
What it is
This blend combines synthetic BPC-157 with a product described as TB-500. A stated total mass does not establish the amount or molecular identity of each component.
The proposed rationale links BPC-157-associated vascular signalling with thymosin-related cell movement. Biological overlap is not proof of synergy, and combined exposure adds uncertainty.
Why people ask about it
Enquiries commonly concern whether a single blend offers more than either ingredient alone for injury-related goals.
What the science says
BPC-157 evidence is predominantly preclinical, while human thymosin beta-4 studies concern specific molecules and formulations. Controlled human studies establishing the safety or benefit of this exact combination are lacking.
Is it right for me?
Before any payment, an online consultation and clinician approval must address the BPC-157/TB-500 combination itself rather than relying on separate ingredient claims.
How Welcuren works
Complete a short online consultation about your health and goals.
A clinician reviews your answers, may ask follow-up questions, and decides whether this treatment is appropriate for you.
You only pay once treatment is approved. Our licensed facility then dispatches it with full instructions, on tracked global delivery.
Safety
Combining incompletely characterised substances may create interactions or adverse effects that single-ingredient reports miss. Unverified component ratios, allergy, pregnancy, breastfeeding and cancer history need consideration; your clinician will advise
Questions
Does 10mg mean 5mg of each ingredient?
Not necessarily; the total label alone does not disclose the component ratio.
Has this blend shown synergy in people?
No reliable controlled clinical evidence establishes a synergistic recovery outcome for this combination.
Can thymosin beta-4 trial results validate the whole blend?
A study of one defined molecule cannot establish the performance of a mixed product.
Is a blend easier to assess if side effects occur?
Multiple ingredients can make attribution of an adverse reaction more difficult.
This information is educational and not a substitute for advice from your clinician. Prescription treatments are only supplied after a clinical consultation.
Often considered together
Many clients start with a blood test so their clinician has a full picture.
ARA-290 (Cibinetide) 10mgARA-290 (Cibinetide) 10mg
ARA-290 (Cibinetide) 10mg is an investigational erythropoietin-derived peptide, considered only after online consultation and clinician approval.
BPC-157 5mgBPC-157 5mg
A synthetic 15-amino-acid peptide with predominantly rodent evidence and no established clinical benefit for injury recovery.
GLOW Blend (BPC-157 + TB-500 + GHK-Cu) 70mgGLOW Blend (BPC-157 + TB-500 + GHK-Cu) 70mg
GLOW Blend combines BPC-157, TB-500 and GHK-Cu in a branded pre-filled pen, available only following online consultation and clinician approval.